IDEAYA Biosciences (IDYA) Competitors

IDEAYA Biosciences (NASDAQ:IDYA) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.

Which has stronger valuation and earnings, IDYA or ROIV?

Roivant Sciences has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$23.39M	88.24	-$112.96M	-$2.33	-10.25
Roivant Sciences	$124.79M	66.33	$4.35B	$5.65	2.01

Does the media favor IDYA or ROIV?

In the previous week, IDEAYA Biosciences and IDEAYA Biosciences both had 5 articles in the media. Roivant Sciences' average media sentiment score of 0.91 beat IDEAYA Biosciences' score of 0.74 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, IDYA or ROIV?

IDEAYA Biosciences has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Do analysts rate IDYA or ROIV?

IDEAYA Biosciences currently has a consensus price target of $53.67, indicating a potential upside of 124.73%. Roivant Sciences has a consensus price target of $17.93, indicating a potential upside of 57.68%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe IDEAYA Biosciences is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.94
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Does the MarketBeat Community prefer IDYA or ROIV?

IDEAYA Biosciences received 90 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 71.57% of users gave IDEAYA Biosciences an outperform vote.

Company	Underperform	Outperform
IDEAYA Biosciences	Outperform Votes 141 71.57%	Underperform Votes 56 28.43%
Roivant Sciences	Outperform Votes 51 77.27%	Underperform Votes 15 22.73%

Do insiders and institutionals have more ownership in IDYA or ROIV?

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 3.5% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Is IDYA or ROIV more profitable?

Roivant Sciences has a net margin of 3,827.42% compared to IDEAYA Biosciences' net margin of 0.00%. Roivant Sciences' return on equity of -14.65% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-19.42%	-18.63%
Roivant Sciences	3,827.42%	-14.65%	-13.19%

Summary

Roivant Sciences beats IDEAYA Biosciences on 11 of the 18 factors compared between the two stocks.